Pfizer Gains Traction With Padcev, Lorbrena — Market Talk

What happened

Pfizer said its bet on new products is paying off. In the third quarter, revenue from recently launched and acquired products grew 32%. These include acquired bladder-cancer treatment Padcev and developed lung-cancer drug Lorbrena, as Pfizer offsets falling Covid product demand.

Confirmed

Global impact / market context

Pfizer is replacing shrinking Covid revenue with newer medicines and bought treatments. A 32% sales increase in these products shows the strategy is adding revenue, which matters because it helps offset declining Covid demand and supports future earnings as older products lose ground.

Analyst inference

Pfizer is shifting from pandemic-era Covid sales toward a broader portfolio of cancer drugs and other new treatments, including weight-loss drugs. Investors weigh whether these newer products can grow fast enough to replace lost Covid revenue and justify the company's acquisition and research spending.

Analyst inference

What to watch

1. Watch whether Pfizer's recently launched and acquired products keep growing, after third-quarter revenue rose 32% for this group. Confirmed
2. Watch for updates on Padcev and Lorbrena sales, since Pfizer highlighted these cancer treatments as contributors to newer-product growth. Proposed
3. Watch how fast Covid product demand falls, because deeper declines would raise pressure on newer medicines to carry total company revenue. Analyst inference

Evidence

• Original source link unavailable